James Maitland is a leading voice in the evolution of medical device manufacturing, specializing in the intersection of robotics and industrial IoT. With a career dedicated to helping organizations transition from manual, reactive processes to sophisticated, data-driven ecosystems, his expertise is particularly relevant as the industry navigates a massive shift toward domestic production. As reshoring evolves from a theoretical discussion into a strategic necessity, James provides the technical and strategic roadmap for manufacturers looking to scale capacity without compromising on quality or intellectual property security.
In this conversation, we explore the complexities of rebuilding manufacturing operations from the ground up, the critical role of system integration, and how AI is transforming the long-term vision of the factory floor. We also delve into the changing nature of the workforce and how “design for manufacturing” serves as a linchpin for successful automation.
Manufacturers are currently facing a paradox where 90% believe increasing capacity is vital to their competitive position, yet 40% have paused investments due to uncertainty. What do you believe is the primary hurdle keeping these leaders from moving forward with their reshoring plans?
The hesitation we see in four out of 10 manufacturers often stems from the sheer weight of the decision-making process when moving away from an established overseas model. Leaders are no longer willing to build new operations on outdated systems, but the leap to a “ground zero” domestic facility involves significant risk and a complete rethinking of the enterprise architecture. We saw how the pandemic forced the industry into a reactive mode, where machines had to be built in days just to keep up, and that experience left a lasting scar; nobody wants to be in that vulnerable position again. Now, the push is driven by a desire to protect intellectual property and maintain tighter regulatory control, but the fear of choosing the wrong technological path often leads to “analysis paralysis.” It is a high-reward scenario, but it requires a level of certainty in the technology stack that many feel they lack in the current climate.
Integration was cited by 47% of decision-makers as the top barrier to optimization. When a company moves production back home, how should they approach a rebuild to ensure that equipment, software, and data infrastructure actually work in harmony?
The mistake many make is trying to reproduce a foreign model domestically, but reshoring is the perfect time to address the fact that your MES, computers, and physical hardware need to be part of a single, cohesive nervous system. When 47% of your peers are struggling with integration, the solution is to stop viewing the facility, the equipment, and the data as separate silos and start treating them as a unified project from day one. You have to look at how every sensor on the floor feeds into the enterprise system to provide real-time insights that actually drive capacity. By starting from scratch, you can proactively design out the bottlenecks that usually occur when you try to bolt new software onto legacy hardware. This holistic approach ensures that as you scale, the data flow remains seamless, which is the only way to achieve true optimization in a modern medical environment.
Looking at the landscape from 2026 through the next three years, 84% of leaders see AI as essential for scaling. How can a manufacturer ensure their reshored infrastructure is ready to support these advanced analytics without over-investing in speculative technology?
The key to being AI-ready is building a robust data infrastructure during the initial reshoring phase so that you aren’t trying to “retro-fit” intelligence later. Since 84% of manufacturers recognize that AI will be the defining factor in how they adapt and scale through 2029, the investment must focus on standardized data collection from every robot and assembly station. If your systems are integrated correctly from the start, AI can eventually take over complex tasks like predictive maintenance and real-time quality adjustments without requiring a total overhaul of the line. We are moving toward a period where the facility itself becomes an evolving entity that learns from its own production cycles. Ensuring your reshoring plan includes high-speed connectivity and modular software architectures today means you can plug in AI modules as they mature over the coming years.
You have often discussed the importance of rethinking “manufacturability” during the reshoring process. How does standardizing something as simple as a component or a mechanical process change the entire ROI of an automated domestic line?
When advanced medical devices first hit the market, designers often focused on the clinical outcome while neglecting the long-term manufacturing logistics, which is why we see so many bottlenecks today. Reshoring provides a unique window to ask if we can use the same mechanics across multiple drug delivery platforms or if we can standardize a simple component like a spring to streamline the supply chain. By improving the design for manufacturing, you make automation significantly easier and more cost-effective because the robots are handling consistent, predictable parts rather than custom outliers. This standardization doesn’t just improve capacity today; it builds a foundation where future products can be launched on the same lines with minimal retooling. It turns the manufacturing floor into a flexible asset rather than a rigid, single-purpose expense.
With 42% of the industry citing inadequate staffing as a barrier to optimization, how does the role of the human operator evolve when a facility transitions to a high-tech, reshored environment?
Staffing challenges are real, but reshoring allows us to reallocate our human capital into roles that are far more rewarding and impactful than simple assembly. Instead of having a person manually snapping two parts together or applying adhesive for eight hours, that same employee can be upskilled to manage quality inspection, oversee robot maintenance, or “teach” the automation systems new tasks. This shift requires a workforce strategy that goes hand-in-hand with the technology rollout, ensuring that the 42% of manufacturers facing labor shortages are actually doing more with the people they have. We find that when employees move into these technical positions, engagement increases and the error rates associated with manual labor drop significantly. It’s about building an environment where humans and robots work in a symbiotic relationship, each focusing on what they do best.
Beyond the direct labor costs, how should executives calculate the true value of having production “in their own backyard” regarding quality and patient safety?
The ROI of reshoring is often found in the “hidden” costs of overseas production, such as the financial impact of poor quality components or the risk of intellectual property theft. When you bring production home, you gain absolute control over the consistency of the manufacturing process, which directly correlates to patient safety—the number one priority in our industry. Automation provides a level of repeatability that manual overseas lines simply cannot match, reducing the likelihood of recalls that can cost a company millions and damage its reputation. Having the engineering team in the same time zone as the production floor allows for rapid iteration and troubleshooting, ensuring that any quality drift is caught and corrected in real-time. Ultimately, the peace of mind that comes from a secure, domestic supply chain and a higher standard of quality control is a value that far outweighs a simple per-unit cost comparison.
What is your forecast for the medical device reshoring trend?
I predict that over the next few years, we will see a massive consolidation of manufacturing “ecosystems” where reshoring is no longer an outlier but the standard for any device involving sensitive IP or complex electronics. As AI and robotics become even more deeply integrated, the cost gap between domestic and overseas production will continue to shrink, making the benefits of proximity, quality, and speed the dominant factors in boardrooms. We will likely see a shift where 125 of the top manufacturers—much like those in recent surveys—move toward fully autonomous “lights-out” shifts for high-volume components, while keeping highly skilled human teams for complex assembly and oversight. This will create a more resilient, responsive domestic industry that can pivot within days rather than months when the next global supply chain disruption hits. Manufacturers who invest in this “ground zero” rebuilding now will be the ones defining the market by the end of the decade.
